ATE324902T1 - Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2 - Google Patents

Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2

Info

Publication number
ATE324902T1
ATE324902T1 AT99958757T AT99958757T ATE324902T1 AT E324902 T1 ATE324902 T1 AT E324902T1 AT 99958757 T AT99958757 T AT 99958757T AT 99958757 T AT99958757 T AT 99958757T AT E324902 T1 ATE324902 T1 AT E324902T1
Authority
AT
Austria
Prior art keywords
orf virus
binds
activates
vegf receptor
growth factor
Prior art date
Application number
AT99958757T
Other languages
English (en)
Inventor
Lyn M Wise
Andrew A Mercer
Loreen J Savory
Stephen B Fleming
Steven A Stacker
Original Assignee
Ludwig Inst Cancer Res
Univ Otago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Univ Otago filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE324902T1 publication Critical patent/ATE324902T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99958757T 1998-11-02 1999-11-02 Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2 ATE324902T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10668998P 1998-11-02 1998-11-02
US10680098P 1998-11-03 1998-11-03

Publications (1)

Publication Number Publication Date
ATE324902T1 true ATE324902T1 (de) 2006-06-15

Family

ID=26803915

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99958757T ATE324902T1 (de) 1998-11-02 1999-11-02 Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2

Country Status (8)

Country Link
US (2) US6541008B1 (de)
EP (1) EP1126863B1 (de)
JP (1) JP2003517275A (de)
AT (1) ATE324902T1 (de)
AU (1) AU775956B2 (de)
DE (1) DE69931178T8 (de)
NZ (1) NZ511119A (de)
WO (1) WO2000025805A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
WO2002060950A2 (en) 1994-11-14 2002-08-08 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US6965010B2 (en) 2000-02-25 2005-11-15 Licentia, Ltd. Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
CA2415397C (en) * 2000-07-11 2011-04-26 Bayer Aktiengesellschaft Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer
DE10122451A1 (de) * 2000-07-11 2002-04-04 Bayer Ag Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs
EP1341914A2 (de) 2000-12-07 2003-09-10 Sangamo Biosciences Inc. Regulation der angiogenese durch zinkfinger-proteine
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CN1555488A (zh) * 2001-07-12 2004-12-15 路德维格癌症研究院 淋巴管内皮细胞物质及方法
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
AU2002336866B8 (en) * 2001-11-01 2009-04-23 The University Of British Columbia Diagnosis and treatment of infectious diseases through indel-differentiated proteins
AU2003297282A1 (en) * 2002-11-14 2004-06-15 Cornell Research Foundation, Inc. Protection of cardiac myocardium
EP2647645B1 (de) * 2002-12-17 2016-07-27 AiCuris GmbH & Co. KG Rekombinante Proteine des Parapoxivirus Ovis und pharmazeutische Zusammensetzungen daraus
EP2351769A3 (de) * 2002-12-17 2011-11-02 AiCuris GmbH & Co. KG Rekombinante Proteine des Parapoxivirus Ovis und pharmazeutische Zusammensetzungen daraus
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
EP1635860A2 (de) * 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Verwendung von vegf-c oder vegf-d in der wiederherstellende chirurgie
WO2005016963A2 (en) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
JP2005110508A (ja) * 2003-10-02 2005-04-28 Nec Soft Ltd 血管内皮増殖因子受容体２型に対する特異的結合性を有するヘビ毒由来血管内皮増殖因子様タンパク質と用途
US20060024302A1 (en) 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
DE602006020881D1 (de) 2005-08-15 2011-05-05 Vegenics Pty Ltd Enen eigenschaften
AU2013213745B2 (en) * 2005-10-06 2015-10-29 Trophogen, Inc. VEGF analogs and methods of use
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
DK2548578T3 (da) 2006-05-17 2014-10-06 Ludwig Inst Cancer Res Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme
US8741839B2 (en) 2009-01-18 2014-06-03 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
EP2431168B1 (de) 2010-09-20 2013-05-01 Bekaert Textiles N.V. Abdeckmaterial
CA2873881A1 (en) * 2012-05-18 2013-11-21 Stephen Bruce Fleming Combination treatments and compositions for wound healing
US10457713B2 (en) 2012-07-30 2019-10-29 Trophogen, Inc. Glycoprotein hormone long-acting superagonists
PT3572515T (pt) 2012-07-30 2021-10-22 Trophogen Inc Superagonistas de ação prolongada de hormonas glicoproteicas
SMT202000088T1 (it) 2013-02-18 2020-03-13 Vegenics Pty Ltd Molecole leganti ligandi e relativi usi
CN105873602A (zh) 2013-11-05 2016-08-17 特洛佛根股份有限公司 糖蛋白激素长效超激动剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
AU718141B2 (en) * 1996-02-28 2000-04-06 Bayer Healthcare Ag Parapoxviruses which contain foreign DNA, their preparation and their use in vaccines
EP0904393A4 (de) * 1996-03-29 1999-09-08 Univ Otago Parapockenvirus-vektoren
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)

Also Published As

Publication number Publication date
EP1126863B1 (de) 2006-05-03
WO2000025805A8 (en) 2000-08-31
EP1126863A4 (de) 2003-01-02
AU1605300A (en) 2000-05-22
AU775956B2 (en) 2004-08-19
DE69931178D1 (de) 2006-06-08
EP1126863A1 (de) 2001-08-29
US6541008B1 (en) 2003-04-01
NZ511119A (en) 2004-04-30
US20030211101A1 (en) 2003-11-13
DE69931178T2 (de) 2007-02-22
WO2000025805A1 (en) 2000-05-11
DE69931178T8 (de) 2007-06-28
JP2003517275A (ja) 2003-05-27

Similar Documents

Publication Publication Date Title
ATE324902T1 (de) Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2
CY1119512T1 (el) Αντισωματα του υποδοχεα 1 της ιντερφερονης αλφα και οι χρησεις αυτων
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
PT817648E (pt) Antagonistas do factor do crescimento de celulas endoteliais vasculares
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
ATE407697T1 (de) Erythropoietin immunglobulin fusionsproteine
CY1107475T1 (el) Αναστολεις ρο-κινασης
DK1325130T3 (da) Nogo-Receptorhomologer
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE363531T1 (de) Claudin polypeptide
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
CY1110418T1 (el) Αναστολη της αλληλεπιδρασης μεταξυ οξειδωμενων πρωτεϊνων και cd36 ή ο μηχανισμος δρασης τους
NO20026286D0 (no) Nye peptider
EA202092229A1 (ru) Мутеины cd4 и способы их применения
YU21292A (sh) Insekticidno efektivni peptidi
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
DE502005010722D1 (de) Farbverändernde mittel mit moringa extrakt
ATE469171T1 (de) Neue insektizide proteine von bazillus thuringiensis
ATE521640T1 (de) Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
WO2006068481A3 (en) Novel necrosis and ethylene inducing proteins from botrytis
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof
WO2021081515A3 (en) Compositions and methods for the treatment of human immunodeficiency virus
ATE492564T1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties